#USA #New York #Conference #Immunic #Vidofludimus

Immunic's Participation in March Conferences

Immunic, Inc. (Nasdaq: IMUX), a pioneering biotechnology company focused on developing novel oral therapies for chronic inflammatory and autoimmune diseases, has announced its participation in several key conferences throughout March. These events will spotlight the company's innovative solutions and the latest developments in their clinical pipeline.

Upcoming Conferences

34th Annual Meeting of the Society for Virology

From March 4 to 7, Immunic will take part in the 34th Annual Meeting of the Society for Virology held in Hamburg, Germany. Two compelling abstracts authored by their team have been accepted for presentation:

• - Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity

Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Abstract Talk: O 081
Session: Antiviral therapy and resistance I
Date: March 6, 2025
Time: 9:30-9:45 AM CET (3:30-3:45 AM ET)

• - Title: Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity

Presenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, Immunic
Abstract Talk: O 112
Session: Antiviral therapy and resistance II
Date: March 7, 2025
Time: 11:00-11:15 AM CET (5:00-5:15 AM ET)

Details of these presentations will also be available on Immunic's official website under the “Events and Presentations” section.

Leerink Partners Global Healthcare Conference

Following the Society for Virology meeting, Immunic's leadership will engage at the Leerink Partners Global Healthcare Conference from March 10 to 12 in Miami. On March 12 at 10:00 AM ET, Dr. Daniel Vitt, CEO, will participate in a fireside chat discussing the company's vision and developments in the healthcare landscape. This will also be accessible via webcast on Immunic's website.

Moreover, key executives including Glenn Whaley, CFO, and Jessica Breu, VP of Investor Relations, will be involved in scheduled one-on-one meetings with investors during the conference.

Immunic's Innovative Pipeline

Immunic is at the forefront of biotechnology with its lead product, Vidofludimus calcium (IMU-838), advancing through phase 3 and phase 2 clinical trials for multiple sclerosis treatment. The therapy has demonstrated promising effects against various forms of the disease, including both relapsing and progressive types, as well as moderate-to-severe ulcerative colitis. The drug's efficacy is attributed to its dual-action mechanism as a nuclear receptor-related 1 (Nurr1) activator, coupled with its role in inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).

Additionally, Immunic is developing IMU-856, which targets Sirtuin 6 (SIRT6) to enhance intestinal barrier function, indicating significant implications for gastrointestinal diseases, including celiac disease and inflammatory bowel diseases.

With a commitment to advancing biopharmaceutical research, Immunic looks toward these conferences as crucial opportunities to share insights, foster collaborations, and invigorate discussions around their pivotal research and therapeutic advancements.

For further details on Immunic's participation at these conferences, or to learn more about their products and services, please visit www.imux.com.